U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07643935) titled 'Prognostic Value of 177Lutetium-PSMA Single Photon Emission Tomography and Timing of Response' on May 06.
Brief Summary: 177Lutetium-PSMA-617 is an established treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). Early response assessment is critical for optimizing patient management. Response Evaluation Criteria in Prostate Imaging (RECIP) 1.0, initially developed for Positon Emission Tomography (PET) with 68Ga-PSMA, have demonstrated prognostic value, particularly after two treatment cycles. Recent studies suggest that SPECT at cycle 2 provides prognostic information, although it reflects only the f...